Qiagen N.V. (QIA.DE)
- Previous Close
37.94 - Open
38.07 - Bid 38.81 x 48300
- Ask 38.83 x 51100
- Day's Range
38.01 - 38.90 - 52 Week Range
33.75 - 44.81 - Volume
834,392 - Avg. Volume
660,626 - Market Cap (intraday)
8.683B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
27.88 - EPS (TTM)
1.39 - Earnings Date --
- Forward Dividend & Yield 1.18 (2.94%)
- Ex-Dividend Date Jan 30, 2024
- 1y Target Est
47.90
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
www.qiagen.com5,191
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: QIA.DE
Performance Overview: QIA.DE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QIA.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QIA.DE
Valuation Measures
Market Cap
8.50B
Enterprise Value
8.94B
Trailing P/E
26.60
Forward P/E
19.01
PEG Ratio (5yr expected)
1.26
Price/Sales (ttm)
4.62
Price/Book (mrq)
2.36
Enterprise Value/Revenue
4.55
Enterprise Value/EBITDA
12.99
Financial Highlights
Profitability and Income Statement
Profit Margin
17.37%
Return on Assets (ttm)
4.49%
Return on Equity (ttm)
9.38%
Revenue (ttm)
1.97B
Net Income Avi to Common (ttm)
341.3M
Diluted EPS (ttm)
1.39
Balance Sheet and Cash Flow
Total Cash (mrq)
1.06B
Total Debt/Equity (mrq)
44.91%
Levered Free Cash Flow (ttm)
156.91M
Research Analysis: QIA.DE
Company Insights: QIA.DE
QIA.DE does not have Company Insights